Research Tissue Bank
3 other identifiers
observational
963
2 countries
11
Brief Summary
This study that will allow for the preservation and/or storage of a small portion one or more of the following tissues:
- Peripheral blood
- Bone marrow
- Bone marrow biopsy
- A phlebotomized unit of blood
- Spleen cells
- Toenail clippings This material will be used for the study of Myeloproliferative Disorders (MPD) by researchers. The goals of this research study are to understand the causes of MPDs, how to diagnose them more easily and how to treat them better. MPD is a disease affecting hematopoietic stem cells. Hematopoietic stem cells are cells that make blood cells. These stem cells grow in the center portion of the bones called bone marrow. Under some conditions, these cells are also found in blood. There are several diseases, which are classified as MPD. These include polycythemia vera (too many red blood cells), essential thrombocythemia (too many platelets), and idiopathic myelofibrosis (abnormal blood cells and fibers build up in the bone marrow). These syndromes carry a high risk of developing leukemia. It is important to continue to learn more about these blood cancers and to learn more about the effectiveness and potential side effects of various treatments.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2007
Longer than P75 for all trials
11 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2007
CompletedFirst Submitted
Initial submission to the registry
April 23, 2008
CompletedFirst Posted
Study publicly available on registry
April 25, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 27, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
March 27, 2017
CompletedJuly 5, 2019
July 1, 2019
9.6 years
April 23, 2008
July 2, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To collect and store tissue specimens from patients with MPDs including PV, IM, ET. The samples will be used to conduct laboratory investigations to help define mechanisms involved in the pathophysiology and treatment of these disorders.
3 years
Eligibility Criteria
Patients diagnosed with Philadelphia chromosome negative myeloproliferative disorders (MPD) polycythemia vera (PV), idiopathic myelofibrosis (IM), and essential thrombocythemia (ET) are eligible and not currently participating in any MPD-RC treatment studies.
You may qualify if:
- Patients diagnosed with Philadelphia chromosome negative myeloproliferative disorders (MPD) polycythemia vera (PV), idiopathic myelofibrosis (IM), and essential thrombocythemia (ET) are eligible.
- Newly diagnose MPD patients as well as previously treated for a MPD are eligible.
- Signed informed consent is required from each patient at the time of enrollment.
You may not qualify if:
- Patients currently participating in experimental treatment arms of MPD-RC protocols, or other experimental treatment protocols are not eligible during the period they are on study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (11)
Palo Alto Medical Foundation Research Institute
Palo Alto, California, 94301, United States
Weill Cornell University
Washington D.C., District of Columbia, 10065, United States
University of Georgetown
Washington D.C., District of Columbia, 20057, United States
University of Illinois at Chicago
Chicago, Illinois, 60612, United States
Johns Hopkins
Baltimore, Maryland, 21205, United States
Roswell Park
Buffalo, New York, 14263, United States
Mount Sinai Medical Center
New York, New York, 10029, United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19107, United States
University of Utah
Salt Lake City, Utah, 84102, United States
Ospedali Riuniti di Bergamo
Bergamo, IL, Italy
University of Florence
Florence, IL, 60302, Italy
Biospecimen
Blood, bone marrow, bone marrow biopsy, toenail clippings, phlebotomized blood, spleen cells
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Rona S Weinberg, PhD
Myeloproliferative Disorders-Research Consortium
- PRINCIPAL INVESTIGATOR
Lewis Silverman, MD
Icahn School of Medicine at Mount Sinai
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 23, 2008
First Posted
April 25, 2008
Study Start
September 1, 2007
Primary Completion
March 27, 2017
Study Completion
March 27, 2017
Last Updated
July 5, 2019
Record last verified: 2019-07